SK Biopharmaceuticals remains in red in Q2
All News
09:52 August 10, 2021
SEOUL, Aug. 10 (Yonhap) -- SK Biopharmaceuticals Co. on Tuesday reported its second-quarter net loss of 67 billion won (US$58.4 million), remaining in the red compared with a year ago.
The company said in a regulatory filing that it continued to post an operating loss of 65.1 billion won for the April-June period, compared with a loss of 57.8 billion won a year earlier. Revenue rose 1060.7 percent to 24 billion won.
(END)
Issue Keywords
Most Liked
-
'Queen of Tears' weaves rich tapestry of Korean contemporary art -
Ateez member Yunho throws first pitch at MLB match between Dodgers, Mets -
N. Korea says Kim guided simulated nuclear counterattack drills for 1st time -
N. Korea calls envisioned U.S. aid to Ukraine 'hallucinogen' -
N. Korea calls on party propaganda officials to work harder
Most Saved
-
'Queen of Tears' weaves rich tapestry of Korean contemporary art -
Experts see possibility of N.K. conducting nuclear test before U.S. presidential vote -
Details of meeting between Yoon, opposition leader undecided: presidential office -
N. Korea says Kim guided simulated nuclear counterattack drills for 1st time -
Looming weekly closure of major hospitals feared to worsen medical service crisis
-
Indonesia coach left with mixed feelings after eliminating native S. Korea in Olympic football qualifiers -
S. Korea eliminated in Olympic football qualifiers as poor defense, undisciplined play prove costly -
ADOR CEO calls conflict with Hybe 'worst experience of my life' -
(LEAD) 10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification -
S. Korea to acquire SM-3 shipborne missiles by 2030
